AD 182
Alternative Names: AD-182; atomoxetine/orexin antagonistLatest Information Update: 01 Feb 2023
At a glance
- Originator Apnimed
- Class Propylamines; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Orexin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sleep apnoea syndrome
Most Recent Events
- 01 Feb 2023 No development reported - Phase-II for Sleep apnoea syndrome in USA (PO)
- 02 Jun 2022 Efficacy and adverse events data from a phase II trial in Obstructive sleep apnea released by Apnimed
- 16 Nov 2021 Safety and efficacy data from phase II trial in SLeep apnoea syndrome released by Apnimed